索磷布韦维帕他韦片治疗慢性丙型病毒性肝炎的效果分析  

Therapeutic effect of sofosbuvir and velpatasvir tablets on chronic hepatitis C

作　　者：李慧霞 郭亚亚 詹春艳 Li Huixia;Guo Yaya;Zhan Chunyan(No.988 Hospital of the Joint Logistic Support Force of PLA of China,Jiaozuo 454000,China)

机构地区：[1]中国人民解放军联勤保障部队第九八八医院,焦作454000

出　　处：《中国实用医刊》2024年第10期94-96,共3页Chinese Journal of Practical Medicine

摘　　要：目的分析索磷布韦维帕他韦片治疗慢性丙型病毒性肝炎(HCV)的临床效果。方法分析性研究。选取2020年5月至2023年5月联勤保障部队第九八八医院收治的慢性HCV患者100例, 按随机数字表法分为常规组和研究组, 每组50例。常规组予以干扰素+利巴韦林治疗, 研究组予以索磷布韦维帕他韦片治疗。比较两组临床疗效、肝功能[天冬氨酸转氨酶(AST)、总胆红素(TBIL)、丙氨酸转氨酶(ALT)]水平、HCV-RNA水平及不良反应发生率。结果研究组总有效率(96.00%, 48/50)高于常规组(74.00%, 37/50), P<0.05。治疗后, 研究组TBIL、ALT、AST水平均低于常规组(P均<0.05);治疗后, 研究组HCV-RNA水平低于常规组(P<0.05);研究组不良反应发生率(14.00%, 7/50)低于常规组(42.00%, 21/50), P<0.05。结论慢性HCV患者采用索磷布韦维帕他韦片治疗, 可提高治疗效果, 降低HCV-RNA水平, 且可改善肝功能, 安全性更高。Objective To investigate the clinical effect of sofosbuvir and velpatasvir tablets in the treatment of chronic hepatitis C(HCV).Methods Analytical research was adopted in this study.A total of 100 patients with chronic HCV treated in No.988 Hospital of the Joint Logistic Support Force of PLA of China from May 2020 to May 2023 were selected,and they were divided into a conventional group and a study group by random number tabe method,with 50 cases in each group.The conventional group was treated with interferon combined with ribavirin,while the study group was treated with sofosbuvir and velpatasvir tablets.The clinical effect,liver function assessed by aspartate transaminase(AST),total bilirubin(TBIL)and alanine transaminase(ALT),levels of HCV-RNA and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the study group(96.00%,48/50)was higher than that of the conventional group(74.00%,37/50),P<0.05.After treatment,the levels of TBIL,ALT and AST in the study group were lower than those in the conventional group(all P<0.05).After treatment,the HCV-RNA level in the study group was lower than that in the conventional group(P<0.05).The incidence of adverse reactions in the study group(14.00%,7/50)was lower than that in the conventional group(42.00%,21/50),P<0.05.Conclusions Sofosbuvir and velpatasvir tablets in the treatment of chronic HCV can improve treatment efficacy,reduce HCV-RNA level,and improve liver function,with higher safety.

关 键 词：丙型病毒性肝炎 慢性 索磷布韦维帕他韦 肝功能 

分 类 号：R512.63[医药卫生—内科学]